4-(1-ethoxyvinyl)-2-methylsulfanylpyrimidine | 521092-40-0

• 分子结构分类: 有机化合物 - 有机硫化合物 - 硫醚类
• 英文名称: 4-(1-ethoxyvinyl)-2-methylsulfanylpyrimidine
• 英文别名: 4-(1-Ethoxy-vinyl)-2-methylsulfanylpyrimidine；4-(1-ethoxyethenyl)-2-methylsulfanylpyrimidine
• CAS: 521092-40-0
• 化学式: C₉H₁₂N₂OS
• 分子量: 196.273
• InChiKey: LHVJBFNORXFQPN-UHFFFAOYSA-N

物化性质

• 沸点：
  318.2±25.0 °C(Predicted)
• 密度：
  1.13±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  13
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  60.3
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  4-(1-ethoxyvinyl)-2-methylsulfanylpyrimidine 在 盐酸 、 盐酸羟胺 、 sodium acetate 、 三乙胺 作用下， 以 四氢呋喃 、 甲醇 、 二氯甲烷 、 水 、 丙酮 为溶剂， 反应 5.5h， 生成 2,2-dimethoxy-2-(2-methylsulfanylpyrimidin-4-yl)ethylamine
  参考文献：
  名称：

  4-IMIDAZOLIN-2-ONE COMPOUNDS AS p38 MAP KINASE INHIBITORS

  摘要：

  公开号：

  EP1439174B1
• 作为产物：
  描述：

  2-甲硫基-4-氯嘧啶 、 三丁基(1-乙氧基乙烯)锡 在 四(三苯基膦)钯 作用下， 以 甲苯 为溶剂， 生成 4-(1-ethoxyvinyl)-2-methylsulfanylpyrimidine
  参考文献：
  名称：

  EP3885346

  摘要：

  公开号：

文献信息

• PROCESS FOR PRODUCTION OF 4-ACETYLPYRIMIDINES AND CRYSTALS THEREOF
  申请人：Ajinomoto Co., Inc.

  公开号：EP1849761A1

  公开（公告）日：2007-10-31

  Compound (II) is reacted with formate in the presence of an alkali metal alkoxide and the like to give compound (III); then this is reacted with compound (IVa) or compound (IVb) to give compound (V); then this is reacted with compound (VI) to give compound (VII); and then this is deprotected to give compound (I). The present invention provides an industrially advantageous production method of a 4-acetylpyrimidine compound useful as a synthetic intermediate for a pharmaceutical product: wherein X is a methylthio group and the like, R1 is a lower alkyl group and the like, R2 is a lower alkyl group optionally having substituent(s) and the like, M is an alkali metal and X1 is a halogen atom.

  化合物（II）在碱金属烷氧化物等存在下与甲酸酯反应，得到化合物（III）；然后与化合物（IVa）或化合物（IVb）反应得到化合物（V）；然后与化合物（VI）反应得到化合物（VII）；最后去保护得到化合物（I）。本发明提供了一种工业上有利的生产方法，用作药物产品的合成中间体的4-乙酰嘧啶化合物：其中X是甲硫基团等，R1是较低的烷基团等，R2是具有取代基的较低的烷基团等，M是碱金属，X1是卤原子。
• 4-Imidazolin-2-one compounds
  申请人：——

  公开号：US20040204426A1

  公开（公告）日：2004-10-14

  The present invention relates to a compound of the formula [I]: 1 wherein G 1 is an alkyl which is substituted by a halogen atom or an alkoxy, or a group of the formula: 2 wherein ring B is benzene ring which may be substituted, etc., Q 1 and Q 2 maybe the same or different, and each is hydrogen atom, a halogen atom or an alkyl, n is 0, 1, 2, 3 or 4, R 1 is hydrogen atom, an alkyl which may be substituted, a cycloalkyl which may be substituted, a phenyl which may be substituted, etc., Z 1 , Z 2 , Z 3 and Z 4 may be the same or different, and each is CH or N, provided that 3 or more of Z 1 , Z 2 , Z 3 and Z 4 should not be N at the same time, G 2 is hydrogen atom, —NR 3 R 4 , —OR 5 , etc., where R 3 to R 8 each is independently hydrogen atom, an alkyl which may be substituted, an alkenyl, an alkynyl, etc., or a pharmaceutically acceptable salt thereof.

  本发明涉及一种式为[I]的化合物：1其中G1是被卤素原子或烷氧基取代的烷基，或者是公式2的基团：其中环B是苯环，可以取代等；Q1和Q2可能相同或不同，且每个都是氢原子、卤素原子或烷基；n为0、1、2、3或4；R1是氢原子、可取代的烷基、可取代的环烷基、可取代的苯基等；Z1、Z2、Z3和Z4可能相同或不同，每个都是CH或N，但要求Z1、Z2、Z3和Z4中的3个或更多个不能同时为N；G2是氢原子、—NR3R4、—OR5等，其中R3到R8各自独立地是氢原子、可取代的烷基、烯基、炔基等；或其药学上可接受的盐。
• 4-IMIDAZOLIN-2-ONE COMPOUNDS
  申请人：Kubo Akira

  公开号：US20090088422A1

  公开（公告）日：2009-04-02

  The present invention relates to a compound of the formula [I]: wherein G 1 is an alkyl which is substituted by a halogen atom or an alkoxy, or a group of the formula: wherein ring B is benzene ring which may be substituted, etc., Q1 and Q2 may be the same or different, and each is hydrogen atom, a halogen atom or an alkyl, n is 0, 1, 2, 3 or 4, R 1 is hydrogen atom, an alkyl which may be substituted, a cycloalkyl which may be substituted, a phenyl which may be substituted, etc., Z 1 , Z 2 , Z 3 and Z 4 may be the same or different, and each is CH or N, provided that 3 or more of Z 1 , Z 2 , Z 3 and Z 4 should not be N at the same time, G 2 is hydrogen atom, —NR 3 R 4 , —OR 5 , etc., where R 3 to R 8 each is independently hydrogen atom, an alkyl which may be substituted, an alkenyl, an alkynyl, etc., or a pharmaceutically acceptable salt thereof.

  本发明涉及一种式[I]的化合物：其中，G1是被卤素原子或烷氧基取代的烷基，或者是式的基团：其中环B是苯环，可能被取代等，Q1和Q2可以相同也可以不同，且每个是氢原子、卤素原子或烷基，n为0、1、2、3或4，R1是氢原子、可能被取代的烷基、可能被取代的环烷基、可能被取代的苯基等，Z1、Z2、Z3和Z4可以相同也可以不同，且每个是CH或N，但应满足Z1、Z2、Z3和Z4中至少有3个不为N，G2是氢原子、-NR3R4、-OR5等，其中R3至R8各自独立地是氢原子、可能被取代的烷基、烯基、炔基等，或者其药学上可接受的盐。
• 4-imidazolin-2-one compounds
  申请人：Mitsubishi Tanabe Pharma Corporation

  公开号：US07846933B2

  公开（公告）日：2010-12-07

  The present invention relates to a compound of the formula [I]: wherein G1 is an alkyl which is substituted by a halogen atom or an alkoxy, or a group of the formula: wherein ring B is benzene ring which may be substituted, etc., Q1 and Q2 may be the same or different, and each is hydrogen atom, a halogen atom or an alkyl, n is 0, 1, 2, 3 or 4, R1 is hydrogen atom, an alkyl which may be substituted, a cycloalkyl which may be substituted, a phenyl which may be substituted, etc., Z1, Z2, Z3 and Z4 may be the same or different, and each is CH or N, provided that 3 or more of Z1, Z2, Z3 and Z4 should not be N at the same time, G2 is hydrogen atom, —NR3R4, —OR5, etc., where R3 to R8 each is independently hydrogen atom, an alkyl which may be substituted, an alkenyl, an alkynyl, etc., or a pharmaceutically acceptable salt thereof.

  本发明涉及一种式[I]的化合物：其中G1是一种被卤素原子或烷氧基取代的烷基，或者是一个式为的基团：其中环B是苯环，可以取代等，Q1和Q2可以相同也可以不同，每个都是氢原子、卤素原子或烷基，n为0、1、2、3或4，R1是氢原子、烷基（可取代）、取代的环烷基、取代的苯基等，Z1、Z2、Z3和Z4可以相同也可以不同，每个都是CH或N，但要求Z1、Z2、Z3和Z4中的3个或更多不能同时为N，G2是氢原子、—NR3R4、—OR5等，其中R3至R8各自独立地是氢原子、烷基（可取代）、烯基、炔基等，或其药学上可接受的盐。
• AMINOPYRIMIDINE COMPOUND USED FOR INHIBITING ACTIVITY OF PROTEIN KINASE
  申请人：Shenzhen TargetRx, Inc.

  公开号：EP3885346A1

  公开（公告）日：2021-09-29

  The present invention relates to an aminopyrimidine compound having an inhibitory effect on the activity of protein kinase as well as the preparation and use thereof. Specifically, disclosed by the present invention is an aminopyrimidine compound represented by formula (I), or a pharmaceutically acceptable salt, stereoisomer, solvate or hydrate thereof, as well as a pharmaceutical composition comprising said compound and a use method therefor. The method comprises a method for treating cell proliferative diseases and conditions such as cancer and immune diseases.

  本发明涉及一种对蛋白激酶活性具有抑制作用的氨基嘧啶化合物及其制备和使用方法。具体地说，本发明公开了一种由式（I）代表的氨基嘧啶化合物，或其药学上可接受的盐、立体异构体、溶液或水合物，以及包含所述化合物的药物组合物及其使用方法。该方法包括治疗细胞增殖性疾病和病症如癌症和免疫疾病的方法。